作为SIRT2抗剂的生物活性真菌代谢物:对癌症治疗的计算探索
Md Habib Ullah Masum1, Syed Mohammad Lokman2, Kazi Chamonara3
1Department of Genomics and Bioinformatics, Faculty of Biotechnology and Genetic Engineering, Chattogram Veterinary and Animal Sciences University, Khulshi, Bangladesh.
这项研究使用计算方法选了真菌代谢物作为潜在的针对SIRT2的抗癌剂. MSID000672显示出有前途的抗癌潜力,具有良好的安全性和类似药物的特性.
科学领域:
- 生物化学 生物化学
- 计算化学计算化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 赛尔图因2 (SIRT2) 是各种癌症中瘤进展的关键调节剂.
- 向SIRT2为抗癌药物开发提供了一个潜在的战略.
研究的目的:
- 用计算机辅助药物设计 (CADD) 方法选真菌代谢物作为潜在的SIRT2抑制剂.
- 评估已识别的潜在抗癌剂的药物动力学,毒性和结合特征.
主要方法:
- 计算机辅助药物设计 (CADD),包括分子对接,分子动力学和药物信息学.
- 评估ADMET的特性,肝毒性,致癌性和致变性.
- 使用对接,分子动力学,PCA和DCCM,分析结合亲和力,稳定性和构造变化.
主要成果:
- 所有测试的真菌代谢物都表现出良好的药理动力学和安全性,没有观察到肝毒性,致癌性或变异性.
- 分子对接确定了对SIRT2的代谢物具有强烈的结合亲和力,MSID001658 (-10.9 kcal/mol) 和MSID000672 (-10.2 kcal/mol) 的结合亲和力得分最高.
- 分子动力学模拟表明,MSID001658与SIRT2形成稳定的复合体,而MSID000672增强了结构灵活性和溶剂可访问性,表明潜在的治疗疗效.
结论:
- 菌代谢物,特别是MSID000672,显示出作为向SIRT2.2的抗癌剂的显著治疗潜力.
- 通过CADD方法,成功识别了具有良好的安全性概况的类似药物化合物.
- 需要进一步的实验验证,以确认MSID000672.67的抗癌疗效.
更多相关视频
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
相关概念视频
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Drugs that Stabilize Microtubules
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Destabilize Microtubules
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
